While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
This is the phase where the synergistic effects become most apparent
Chandys hypothesis is accurate, the initial worsening might be a sign that the body is starting to heal or correct imbalances that have been present for a long time
There are also inactive forms that are synthetically made (human-made)
The compound was granted GRAS (Generally Recognized as Safe) status by the FDA for use as a food ingredient at low oral doses, but that designation carries no therapeutic implication and does not extend to injectable subcutaneous use in any population [3]